课题基金 / 基金详情

SOFTWARE TO COMPENSATE FOR INTERRUPTIONS IN RADIOTHERAPY

SOFTWARE TO COMPENSATE FOR INTERRUPTIONS IN RADIOTHERAPY
补偿放射治疗中断的软件
批准号:
2106040
负责人:
RAINER K SACHS
金额:
$37.58万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-06-01 至 1998-07-31

项目摘要

项目成果

RAINER K SACHS的其他基金

相关文献

中文摘要
翻译
在所有外照射疗程中,有相当一部分人 计划外中断,即错过了预定的治疗。因为. 细胞损伤修复和肿瘤再繁殖的动力学,设计 额外或增强的治疗,以弥补错过的分数是 不是微不足道的。由于一些个性化补偿方案必须 选择,它应该是合理的使用最先进的放射生物学。在……里面 第一阶段,我们编写了原型软件(RIC,放射治疗中断 补偿器)提供了一系列实用的选择 放射治疗师补偿在治疗期间的计划外中断 延长放射治疗方案。它计算出需要多少剂量才能 产生相同的肿瘤控制(或者,交替产生相同的晚期正常组织 并发症)时,建议的中断补偿方案 取代了原计划的议定书。程序是设计的 作为一个“专家系统”,提供给任何执业的放射治疗师 领先从业者的专业知识,在基于个人计算机的 用户友好的套餐。 在论证了可行性后,我们建议,在此第二阶段应用中, 为了继续在第一阶段启动的研究工作,目标是 在第二阶段结束时生产适销对路的产品 A)采用最先进的科学技术,b)设计和编写 适当的质量控制,c)使用可靠,d)实践可信 临床医生。 建议的商业应用:潜在市场包括超过 全球2500家放射肿瘤学机构。可能约为1-4 每个设施购买的软件副本,每份约900美元。
英文摘要
A significant fraction of all courses of external-beam radiotherapy have unplanned interruptions, i.e. scheduled treatments are missed. Because of the kinetics of cellular damage repair and tumor repopulation, designing extra or augmented treatments to compensate for the missed fractions is non-trivial. Since some individualized compensation regimen must be chosen, it should be rationalized using state-of-the-art radiobiology. In Phase I we wrote prototype software (RIC, the Radiotherapy Interruption Compensator) which produces a range of practical options for the radiotherapist to compensate for unplanned interruptions during an extended radiotherapy regimen. It calculates what doses are needed to produce equal tumor control (or, alternately, equal late normal-tissue complications) when a proposed interruption-compensated regimen is substituted for the originally planned protocol. The program is designed as an "expert system", making available to any practicing radiotherapist the expertise of leading practitioners, in a personal-computer based, user-friendly package. Having demonstrated feasibility, we propose, in this Phase II application, to continue the research effort initiated in Phase I. The goal is to produce, at the end of the Phase II period, a marketable product which is a) scientifically state-of-the-art, b) designed and written with appropriate quality control, c) robust to use, d) credible to practicing clinicians. PROPOSED COMMERCIAL APPLICATION: Potential market consists of more than 2,500 Radiation Oncology facilities worldwide. Potentially about 1-4 copies of the software purchased by each facility, at about $900 per copy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 5 UC Berkley
Updating Chromosome Aberration Simulator (CAS) Software
Updating Chromosome Aberration Simulator (CAS) Software
Updating Chromosome Aberration Simulator (CAS) Software